Lara Alzyoud

Ms. Lara Alzyoud

Al Ain University of Science and Technology, Al Ain, United Arab Emirates
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JFJoviana William Farhat
Joviana William Farhat
LALara Alzyoud
Lara Alzyoud
MAMohammad Alwahsh
Mohammad Alwahsh
BABasem Al-Omari
Basem Al-Omari
Benzofuran is a heterocyclic compound found naturally in plants and it can also be obtained through synthetic reactions. Multiple physicochemical characteristics and versatile features distinguish benzofuran, and its chemical structure is composed of fused benzene and furan rings. Benzofuran derivatives are essential compounds that hold vital biological activities to design novel therapies with enhanced efficacy compared to conventional treatments. Therefore, medicinal chemists used its core to synthesize new derivatives that can be applied to a variety of disorders. Benzofuran exhibited potential effectiveness in chronic diseases such as hypertension, neurodegenerative and oxidative conditions, and dyslipidemia. In acute infections, benzofuran revealed anti-infective properties against microorganisms like viruses, bacteria, and parasites. In recent years, the complex nature and the number of acquired or resistant cancer cases have been largely increasing. Benzofuran derivatives revealed potential anticancer activity with lower incidence or severity of adverse events normally encountered during chemotherapeutic treatments. This review discusses the structure–activity relationship (SAR) of several benzofuran derivatives in order to elucidate the possible substitution alternatives and structural requirements for a highly potent and selective anticancer activity.

2 August 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
LALara Alzyoud
Lara Alzyoud
MGMohammad Ahmad Ghattas
Mohammad Ahmad Ghattas
NANoor atatreh
Noor atatreh
The current pandemic caused by the COVID-19 disease has reached everywhere in the world and has affected every aspect of our lives. As of the current data, the World Health Organization (WHO) has reported more than 300 million confirmed COVID-19 cases worldwide and more than 5 million deaths. Mpro is an enzyme that plays a key role in the life cycle of the SARS-CoV-2 virus, and it is vital for the disease progression. The Mpro enzyme seems to have several allosteric sites that can hinder the enzyme catalytic activity. Furthermore, some of these allosteric sites are located at or nearby the dimerization interface which is essential for the overall Mpro activity. In this review paper, we investigate the potential of the Mpro allosteric site to act as a drug target, especially since they interestingly appear to be resistant to mutation. The work is illustrated through three subsequent sections: First, the two main categories of Mpro allosteric sites have been explained and discussed. Second, a total of six pockets have been studied and evaluated for their druggability and cavity characteristics. Third, the experimental and computational attempts for the discovery of new allosteric inhibitors have been illustrated and discussed. To sum up, this review paper gives a detailed insight into the feasibility of developing new Mpro inhibitors to act as a potential treatment for the COVID-19 disease. Graphical Abstract:

9 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
RMRadwa Essam Mahgoub
Radwa Essam Mahgoub
FMFeda E Mohamed
Feda E Mohamed
LALara Alzyoud
Lara Alzyoud
BABassam R Ali
Bassam R Ali
JFJuliana Ferreira
Juliana Ferreira
MGMohammad Ahmad Ghattas
Mohammad Ahmad Ghattas
The main protease enzyme (Mpro) of SARS-CoV-2 is one of the most promising targets for COVID-19 treatment. Accordingly, in this work, a structure-based virtual screening of 3.8 million ligand libraries was carried out. After rigorous filtering, docking, and post screening assessments, 78 compounds were selected for biological evaluation, 3 of which showed promising inhibition of the Mpro enzyme. The obtained hits (CB03, GR04, and GR20) had reasonable potencies with Ki values in the medium to high micromolar range. Interestingly, while our most potent hit, GR20, was suggested to act via a reversible covalent mechanism, GR04 was confirmed as a noncompetitive inhibitor that seems to be one of a kind when compared to the other allosteric inhibitors discovered so far. Moreover, all three compounds have small sizes (~300 Da) with interesting fittings in their relevant binding sites, and they possess lead-like characteristics that can introduce them as very attractive candidates for the future development of COVID-19 treatments.

9 November 2023 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
LALara Alzyoud
Lara Alzyoud
RMRadwa E. Mahgoub
Radwa E. Mahgoub
FMFeda E Mohamed
Feda E Mohamed
BABassam R. Ali
Bassam R. Ali
JFJuliana Ferreira
Juliana Ferreira
MGMohammad Ahmad Ghattas
Mohammad Ahmad Ghattas

31 December 2023 in Preventive Nutrition and Food Science
Verified
Journal Article
Open access
PDF file
SASuhad Abumweis
Suhad Abumweis
LALara Alzyoud
Lara Alzyoud
SASarah Alqadi
Sarah Alqadi
Suhad Abumweis, Lara Alzyoud, and Sarah Alqadi. Prev Nutr Food Sci 2023;28:377-85. https://doi.org/10.3746/pnf.2023.28.4.377

Verified
Journal Article
Open access
PDF file
FMFeda E Mohamed
Feda E Mohamed
LALara Alzyoud
Lara Alzyoud
MGMohammad Ahmad Ghattas
Mohammad Ahmad Ghattas
MTMohammed Tabouni
Mohammed Tabouni
AFAndré Fienemann
André Fienemann
FJFatma Jasmi
Fatma Jasmi
Sepiapterin Reductase Deficiency (SRD) is a rare inherited neurometabolic disorder caused by variants in the SPR gene, which may lead to developmental delays, psychomotor retardation, and cognitive impairments. Two consanguineous North African and Middle Eastern families are reported with multiple affected individuals presenting with developmental delay, ataxia, hypotonia, fatigue, and ptosis, or parkinsonism and cognitive impairment. Exome sequencing revealed a novel homozygous SPR c.560A>G (p.Glu187Gly) mutation that segregates with disease. According to molecular dynamics analysis, the substitution is predicted to compromise structural integrity, likely affecting ligand binding and catalytic activity. Elevated cerebrospinal fluid sepiapterin and biopterin levels, along with low neurotransmitter levels, were concordant with a genetic diagnosis of SRD and the reclassification of this variant as pathogenic. SRD patients manifest a broad constellation of symptoms, albeit well-managed using low-dose L-dopa/carbidopa. This study highlights the value of genetic testing in expediting early diagnosis and intervention to mitigate the onset of this disorder.